^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    KIT V559

    i
    Other names: KIT, KIT proto-oncogene receptor tyrosine kinase, C-Kit, CD117, PBT, SCFR, Stem Cell Factor Receptor, V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog
    Entrez ID:
    3815
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Associations

    News

    Trials
    10ms
    Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial (clinicaltrials.gov)
    P2, N=40, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
    Trial suspension
    |
    PDGFRA (Platelet Derived Growth Factor Receptor Alpha)
    |
    PDGFRA D842V • KIT L576P • KIT K642E • KIT V559 • KIT V559A • KIT W557
    |
    paclitaxel • Tasigna (nilotinib)
    1year
    Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial (clinicaltrials.gov)
    P2, N=40, Recruiting, National Cancer Institute (NCI) | Initiation date: Sep 2023 --> Dec 2023
    Trial initiation date
    |
    PDGFRA (Platelet Derived Growth Factor Receptor Alpha)
    |
    PDGFRA D842V • KIT L576P • KIT K642E • KIT V559 • KIT V559A • KIT W557
    |
    paclitaxel • Tasigna (nilotinib)
    1year
    Follicular Dendritic Cell Sarcoma With Associated Novel FBXW7 and KMT2C Mutations Identified by Targeted Genome Sequencing (CAP 2023)
    KMT2C A2254T has only been reported in astrocytoma. To our knowledge, this is the first case report of FBXW7 and KMT2C mutations in FDCS, which may indicate biologic and therapeutic relevance (Figure 1.82, A–D).
    FBXW7 (F-Box And WD Repeat Domain Containing 7) • KMT2C (Lysine Methyltransferase 2C) • BIRC3 (Baculoviral IAP repeat containing 3) • CR1 (Complement C3b/C4b Receptor 1) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    KMT2C mutation • MTOR mutation • KIT V559 • MLL3 mutation
    |
    FoundationOne® Heme CDx
    1year
    Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial (clinicaltrials.gov)
    P2, N=40, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PDGFRA (Platelet Derived Growth Factor Receptor Alpha)
    |
    PDGFRA D842V • KIT L576P • KIT K642E • KIT V559 • KIT V559A • KIT W557
    |
    paclitaxel • Tasigna (nilotinib)
    over1year
    Clinicopathological, immunohistochemical, molecular-genetic and risk profiles of gastrointestinal stromal tumors in a cohort of Sudanese patients. (PubMed, Afr Health Sci)
    Nearly half of them correspond to the malignant/high-risk category. The frequency of KIT mutations (79.31%) is in line with the literature.
    Journal • Stroma
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • ANO1 (Anoctamin 1)
    |
    KIT mutation • KIT L576 • KIT V559
    |
    imatinib
    over1year
    Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial (clinicaltrials.gov)
    P2, N=40, Recruiting, National Cancer Institute (NCI) | Initiation date: Jun 2023 --> Sep 2023
    Trial initiation date
    |
    PDGFRA (Platelet Derived Growth Factor Receptor Alpha)
    |
    PDGFRA D842V • KIT L576P • KIT K642E • KIT V559 • KIT V559A • KIT W557
    |
    paclitaxel • Tasigna (nilotinib)
    over1year
    Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial (clinicaltrials.gov)
    P2, N=40, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting | Initiation date: Dec 2022 --> Jun 2023
    Enrollment open • Trial initiation date
    |
    PDGFRA (Platelet Derived Growth Factor Receptor Alpha)
    |
    PDGFRA D842V • KIT L576P • KIT K642E • KIT V559 • KIT V559A • KIT W557
    |
    paclitaxel • Tasigna (nilotinib)
    2years
    LANDSCAPE OF GENOMIC ALTERATIONS IN 115 PATIENTS WITH DESMOID FIBROMATOSIS IN THE AACR GENIE REAL WORLD DATABASE: CLINICAL IMPLICATIONS (CTOS 2022)
    Current treatments include surgery, tyrosine kinase inhibitors (e.g. sorafenib, pazopanib, sunitinib), and NSAIDs while gamma secretase inhibitors are under study. A large cohort of 204 desmoid-type fibromatosis samples analysed by targeted next-generation sequencing at the University Munster revealed imatinib sensitive KIT V559D in addition to AKT1, ALK, EGFR and ERBB2, however, NRG1 and MAFB were not included in the gene panel. Copy number alterations and mutations in NRG1 and MAFB may be relevant to the pathogenesis and a potential targeted therapy of desmoid fibromatosis. Copy number alterations and mutations in NRG1 and MAFB may be relevant to the pathogenesis and a potential targeted therapy of desmoid fibromatosis. Further analyses will be needed to confirm the relevance of these genes. Larger studies that include copy number analysis, whole exome and RNA sequencing are warranted.
    Clinical • Real-world evidence
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ALK (Anaplastic lymphoma kinase) • NOTCH1 (Notch 1) • NRG1 (Neuregulin 1) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • PTCH1 (Patched 1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • FAT1 (FAT atypical cadherin 1) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase) • NOTCH3 (Notch Receptor 3) • MAFB (MAF BZIP Transcription Factor B) • PRKDC (Protein Kinase, DNA-Activated, Catalytic Subunit)
    |
    CTNNB1 mutation • NRG1 mutation • KIT V559
    |
    sorafenib • imatinib • sunitinib • pazopanib